The DA regimen is the most commonly used regimen in clinical practice for the treatment of acute myeloid leukemia and for the induction of remission. Where D is the abbreviation for erythromycin and A is the abbreviation for cytarabine. The usual dose of erythromycin is 40-60 mg per square meter of body surface area, and the usual dose of cytarabine is 100-200 mg per square meter of body surface area, and the usual dose of erythromycin is 3 days and the usual dose of cytarabine is 7 days. After the application of DA regimen, the patient’s peripheral blood, the number of various blood cells will be significantly decreased, the clinical diagnosis of myelosuppression, the patient needs to be given a series of symptomatic support treatment such as blood transfusion, hemostasis, anti-infection. When the patient’s myelosuppression period has resolved and the blood cell count has recovered, the course of the DA regimen will be completed.